Guideline interpretation: the 2021 European Group on Graves′ Orbitopathy Clinical Practice Guidelines for the Medical Management of Graves′ Orbitopathy
10.3760/cma.j.cn311282-20210816-00522
- VernacularTitle:2021年欧洲Graves眼病专家组Graves眼病管理指南解读
- Author:
Zhangfang LI
1
;
Yaosheng LUO
;
Jie SHEN
Author Information
1. 南方医科大学第三附属医院内分泌代谢科，广州 510630
- Keywords:
Graves orbitopathy;
Glucocorticoids;
Mycophenolate mofetil;
Monoclonal antibody
- From:
Chinese Journal of Endocrinology and Metabolism
2022;38(5):359-363
- CountryChina
- Language:Chinese
-
Abstract:
The 2021 European Group on Graves′ Orbitopathy (EUGOGO) Clinical Practice Guidelines for the Medical Management of Graves′ Orbitopathy was released in July, 2021. Based on the 2016 version, the new guidelines updated the first-line management algorithm for patients with Graves′ orbitopathy in moderate-to-severe and active period, provided multiple second-line treatment pathways and made detailed recommendations from aspects of clinical assessment, general measures, and management of specific conditions, etc. At the same time, efficacy evaluation and management during COVID-19 period were explained in detail. The new guidelines also mentioned some novel treatment strategies of GO which still need further efficacy and safety verification.
